SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+16.97%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.2B
AUM Growth
+$1.2B
(+6%)
Cap. Flow
-$60.2M
Cap. Flow
% of AUM
-5%
Top 10 Holdings %
Top 10 Hldgs %
37.95%
Holding
109
New
16
Increased
24
Reduced
36
Closed
22
Top Buys
| 1 |
Grifois
GRFS
|
$40.2M |
| 2 |
Sanofi
SNY
|
$31.7M |
| 3 |
QuidelOrtho
QDEL
|
$31.3M |
| 4 |
Eli Lilly
LLY
|
$17.1M |
| 5 |
Krystal Biotech
KRYS
|
$16.6M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$26M |
| 2 |
Nurix Therapeutics
NRIX
|
$22.2M |
| 3 |
Penumbra
PEN
|
$22.2M |
| 4 |
Vaxcyte
PCVX
|
$18.1M |
| 5 |
Humana
HUM
|
$16.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Iovance Biotherapeutics
IOVA
$807M
| $80.1M | 6.2% | 8,528,500 +980,500 | +13% | +$9.21M |
|
|
2
TG Therapeutics
TGTX
$4.65B
| $59.3M | 4.59% | 2,534,540 -1,111,022 | -30% | -$26M |
|
3
Terns Pharmaceuticals
TERN
$609M
| $51.9M | 4.02% | 6,223,544 +1,275,806 | +26% | +$10.6M |
|
4
Axogen
AXGN
$743M
| $42.1M | 3.26% | 3,005,943 -299,872 | -9% | -$4.2M |
|
|
5
Grifois
GRFS
$6.78B
| $40.2M | 3.11% | +4,521,703 | New | +$40.2M |
|
|
6
Krystal Biotech
KRYS
$4.27B
| $39.5M | 3.06% | 216,979 +90,979 | +72% | +$16.6M |
|
7
C4 Therapeutics
CCCC
$185M
| $37.6M | 2.91% | 6,603,996 +2,552,000 | +63% | +$14.5M |
|
8
United Therapeutics
UTHR
$13.8B
| $36.5M | 2.83% | 101,894 -39,605 | -28% | -$14.2M |
|
|
9
Sanofi
SNY
$121B
| $35.3M | 2.73% | 612,000 +549,500 | +879% | +$31.7M |
|
10
Organogenesis Holdings
ORGO
$653M
| $33.9M | 2.62% | 11,839,876 +320,922 | +3% | +$918K |
|
11
IDEAYA Biosciences
IDYA
$2.15B
| $33.2M | 2.57% | 1,049,314 +355,245 | +51% | +$11.3M |
|
12
Revolution Medicines
RVMD
$7.1B
| $32M | 2.47% | 704,584 -151,594 | -18% | -$6.87M |
|
|
13
QuidelOrtho
QDEL
$1.95B
| $31.3M | 2.42% | +686,000 | New | +$31.3M |
|
14
ESSA Pharma
EPIX
$11.4M
| $26M | 2.01% | 4,288,167 +77,630 | +2% | +$470K |
|
15
Jasper Therapeutics
JSPR
$45.5M
| $25.3M | 1.96% | 1,343,665 +67,475 | +5% | +$1.27M |
|
16
Surmodics
SRDX
$487M
| $24.7M | 1.91% | 637,698 -144,079 | -18% | -$5.59M |
|
|
17
Nurix Therapeutics
NRIX
$714M
| $23.9M | 1.85% | 1,065,834 -990,082 | -48% | -$22.2M |
|
18
10x Genomics
TXG
$1.74B
| $21.5M | 1.66% | 951,000 +232,000 | +32% | +$5.24M |
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $21M | 1.63% | 1,090,984 +264,484 | +32% | +$5.09M |
|
20
Merus
MRUS
$4.98B
| $19.9M | 1.54% | 398,321 +22,000 | +6% | +$1.1M |
|
21
Castle Biosciences
CSTL
$696M
| $18.9M | 1.46% | 662,332 -191,296 | -22% | -$5.46M |
|
|
EDAP
22
EDAP TMS
EDAP
$84.5M
| $18.6M | 1.44% | 7,309,254 +15,526 | +0.2% | +$39.6K |
|
|
ONC
23
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $18.6M | 1.44% | 82,750 -54,950 | -40% | -$12.3M |
|
24
Celcuity
CELC
$2.17B
| $18.6M | 1.44% | 1,245,387 +34,200 | +3% | +$510K |
|
|
25
Eli Lilly
LLY
$657B
| $17.1M | 1.32% | +19,300 | New | +$17.1M |
|